See where vaccine growth is moving next, from mRNA and cancer vaccines to manufacturing capacity.
Vaccine growth is becoming more uneven, with mRNA, cancer vaccines and contract manufacturing outpacing the wider market. Visiongain’s new briefing compares four markets through 2036 and shows where growth is strongest and what could hold it back.
Inside the Report:
➤ Which vaccine markets are growing fastest through 2036
➤ Where mRNA is finding growth beyond COVID
➤ How cancer vaccines could reshape the commercial model
➤ Where manufacturing and CDMO capacity could limit growth
"*" indicates required fields
See where vaccine growth is shifting before strategy, investment and partnership decisions are made.
As growth moves beyond traditional vaccine volumes, companies that understand where demand, platforms and capacity are converging will be better placed to make faster strategy, investment and partnership decisions.
Download the free report to understand:
➤ Where vaccine demand is broadening beyond traditional immunisation
➤ How mRNA is moving from emergency-response technology to repeatable platform strategy
➤ How fill-finish, CDMO access and regional manufacturing could shape execution
➤ Which companies are positioned across vaccines, mRNA, oncology and manufacturing
"*" indicates required fields
"*" indicates required fields
Your shopping cart is empty
Notifications